University of Wisconsin-River Falls, River Falls, WI, USA.
Virulence. 2010 May-Jun;1(3):145-55. doi: 10.4161/viru.1.3.10897.
The objective of the present investigation was to determine whether the bacterium Dietzia subsp. C79793-74, previously shown to inhibit growth of Mycobacterium subsp. paratuberculosis under in vitro culture conditions, has therapeutic value as a probiotic for adult cattle with paratuberculosis. Animals were obtained from several herds with evidence of disease based on seropositivity and/or fecal shedding. Sixty-eight cows with initial evidence of Stage II or III paratuberculosis and 2 with an initial Stage IV disease were evaluated longitudinally. Animals were either treated daily with variable, disease-dependent doses of Dietzia (n = 48) or left untreated (n = 22). Clinical aspects of disease (diarrhea, emaciated, cachectic and appetite) were recorded until the animal recovered or required euthanasia due to advanced clinical paratuberculosis or other severe conditions. Paratuberculosis parameters-antibody serology (ELISA, AGID) and fecal culture-were longitudinally monitored over the lifetime of each animal. The results indicated that daily treatment with Dietzia was therapeutic for paratuberculosis cows based on: (a) longitudinal decline in ELISA values only occurred in animals that were treated; (b) prolonged survival was dependant upon treatment--the length being directly associated with low initial ELISA values; and (c) treated animals were the only ones cured of disease. Further investigations are envisaged to determine optimal, long-term dosages that may result in even better therapeutic outcomes as well as to evaluate potential application for therapy of the Johne's disease, human-counterpart, Crohn's disease.
本研究旨在确定先前在体外培养条件下显示可抑制分枝杆菌亚种生长的细菌 Dietzia subsp. C79793-74 是否具有作为患有副结核病的成年牛的益生菌的治疗价值。动物来自几个具有血清阳性和/或粪便排出物的疾病证据的牛群。68 头具有副结核病 II 期或 III 期初始证据的牛和 2 头具有初始 IV 期疾病的牛进行了纵向评估。动物要么每天接受不同的、取决于疾病的 Dietzia 剂量治疗（n = 48），要么不治疗（n = 22）。记录疾病的临床方面（腹泻、消瘦、消瘦和食欲），直到动物康复或因晚期临床副结核病或其他严重疾病需要安乐死。副结核病参数-抗体血清学（ELISA、AGID）和粪便培养-在每个动物的一生中进行纵向监测。结果表明，每天用 Dietzia 治疗副结核病牛是有效的，这是基于：（a）仅在接受治疗的动物中，ELISA 值才会呈纵向下降；（b）延长的生存取决于治疗-长度与低初始 ELISA 值直接相关；和（c）接受治疗的动物是唯一治愈疾病的动物。进一步的研究旨在确定最佳的长期剂量，这可能会导致更好的治疗效果，并评估对人类克罗恩病的副结核病、人类对应物的潜在治疗应用。
